Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07835971
Active, not recruiting Phase 2

A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential Hypertension

NCT07835971 · tracked via the Priya Life Science China tracker
Sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd
Phase
Phase 2
Started
2025-12-24
Last updated
2026-09-23

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

GW906 →Placebo

GW906: Subcutaneous injection

Placebo: Subcutaneous injection

Study summary

The purpose of this study is to evaluate the effect of GW906 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of GW906.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years, of either sex. * Mean sitting systolic blood pressure (msSBP) ≥ 140 mmHg and \< 180 mmHg at screening. * Willing to participate in the study and provide written informed consent. Exclusion Criteria: * Secondary hypertension. * orthostatic hypotension. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2. * Received an investigational agent within the last 3 months. * Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus. * History of any cardiovascular event within 12 months. * History of intolerance to SC injection(s).

Primary outcome measure(s)

  • Change from baseline in mean sitting systolic blood pressure (msSBP) at Week 12 — Baseline and Month 3
    msSBP will be measured in the office using a validated sphygmomanometer, with the participant seated and resting quietly for at least 5 minutes. The primary endpoint is the change from baseline, calculated as the Week 12 value minus the baseline value, expressed in mmHg

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai, China Shanghai Shanghai Municipality

More Shenzhen Salubris Pharmaceuticals Co., Ltd. trials in China

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population Recruiting
Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants Recruiting
SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a) Active, not recruiting
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease Starting soon
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism Starting soon

Other trials for the same condition

The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy Recruiting
EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Starting soon
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia Enrolling by invitation
Sympathetic Mapping/ Ablation of Renal Nerves Trial Active, not recruiting
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07835971 on ClinicalTrials.gov ↗ ← All trials in China